Classic PNH had the greatest impact on its treatment after the introduction of eculizumab, a monoclonal antibody that prevents the formation of the membrane attack complex by blocking C5 cleavage in C5a and C5b [17] and decreases hemolysis and thromboembolic complications and improves survival[1]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.